Neoleukin Therapeutics (NLTX) Tops Q2 EPS by 1c

Neoleukin Therapeutics (NASDAQ: NLTX) reported Q2 EPS of ($0.20), $0.01 better than the analyst estimate of ($0.21).

For earnings history and earnings-related data on Neoleukin Therapeutics (NLTX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery